PCaution when used during lactation:Caution when used during pregnancy

LCaution when used 

during lactation:Caution when used during lactation

Molecule Info

 | See TERMINOLOGY & ABBREVIATIONS |
Indication(s) & Dosage Uncomplicated lower urinary tract infections
Adult: 1 g 4 times daily for 1-2 wk. Long-term therapy: Reduce daily dose to 2 g.
Child: >3 mth: 50 mg/kg daily in 4 equally divided doses. Long-term therapy: Reduce dose to 30 mg/kg daily. Prophylaxis: 15 mg/kg bid. 
Renal impairment: Reduced doses should be considered.
Hepatic impairment: Reduced doses should be considered.

Shigellosis
Adult: 1 g 4 times daily for 5 days.
Child: â‰¥3 mth: 15 mg/kg 4 times daily for 5 days.
Renal impairment: Reduced doses should be considered.
Hepatic impairment: Reduced doses should be considered.
Administration Should be taken with food.
Overdosage Symptoms: Toxic psychosis, convulsions, increased intracranial pressure, metabolic acidosis, vomiting, nausea, lethargy. Management: Increase fluid admin; supportive measures. Anticonvulsants may be used in severe cases.
Contraindications Hypersensitivity. History of convulsive disorders or porphyria. Infants <3 mth. Severe renal impairment.
Special Precautions Hepatic or moderate renal impairment, severe cerebral arteriosclerosis, G6PD deficiency. Monitor blood counts, renal and hepatic function for treatment >2 wk. Children <18 yr. Elderly. Avoid exposure to sunlight or sunlamps. Pregnancy and lactation.
Adverse Drug Reaction(s) Nausea, vomiting, diarrhoea, abdominal pain; photosensitivity reactions, allergic rash, urticaria, pruritus; visual disturbances, headache, dizziness or vertigo, drowsiness, confusion, depression, excitement, hallucinations, toxic psychoses or convulsions (especially after large doses), intracranial hypertension (especially in infants and young children), metabolic acidosis; peripheral neuropathies, muscular weakness, myalgia; arthralgia, tendon damage; cholestatic jaundice, thrombocytopenia, leucopenia.
Potentially Fatal: Erythema multiforme and Stevens-Johnson syndrome; anaphylactoid reactions. Auto-immune haemolytic anaemia (particularly in elderly patients).
Drug Interactions Absorption reduced by sucralfate, and divalent and trivalent cations e.g. aluminium, calcium, iron, magnesium, zinc. Excretion reduced and plasma concentrations increased with probenecid. Reduced effects with chloramphenicol, nitrofurantoin, tetracycline.
Potentially Fatal: Fatal haemorrhagic enterocolitis may occur when used with high-dose melphalan in children. Increased risk of nephrotoxicity with ciclosporin. May increase effects of oral anticoagulants e.g. warfarin. Please consult detailed drug interactions before prescribing.
Lab Interference May cause false-positive urinary glucose tests using copper reduction methods. May also interfere with 17-ketosteroids and ketogenic steroids determinations.
Pregnancy Category (FDA) Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Storage Oral: Store at room temperature, up to 25°C (77°F).
Pharmacology Nalidixic acid is a 4-quinolone antibacterial. It interferes with the replication of bacterial DNA by inhibiting DNA gyrase activity. It acts against gram-negative bacteria including E. coli, Proteus, Klebsiella, Enterobacter, Salmonella andShigella spp.
Absorption: Rapidly and almost completely absorbed from the GI tract. (oral); peak plasma concentrations after 1-2 hr (oral).
Distribution: Crosses the placenta; enters the breast milk. Protein-binding: 93% (nalidixic acid); 63% (hydroxynalidixic acid).
Metabolism: Partially converted in the liver to hydroxynalidixic acid.
Excretion: Via urine (80-90% as inactive metabolites); faeces (4%); 1-2.5 hr (elimination half-life).
ATC Classification J01MB02 - nalidixic acid; Belongs to the class of other quinolones. Used in the treatment of systemic infections.

Brand/Product Info


Total Products : 12            
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
DIXICON Jayson Pharmaceuticals Ltd. Nalidixic acid 500mg Tablet 100's: 384.00 MRP
DIXICON Suspension Jayson Pharmaceuticals Ltd. Nalidixic acid 300mg/5ml Suspension 50ml: 30.45 MRP
NALID Square Pharmaceuticals Ltd. Nalidixic Acid 500mg Tablet 6x10
NALID PFS Square Pharmaceuticals Ltd. Nalidixic Acid 300mg/5 ml Powder for Suspension 50 ml: 41.86 MRP
NALIDEX Ambee Pharmaceuticals Ltd. Nalidixic acid 500mg Tablet 100's: 407.00 MRP
NALIDEX Suspension Ambee Pharmaceuticals Ltd. Nalidixic acid 250mg/5ml Suspension 50ml: 30.46 MRP
NALIDIXIN Pharmadesh Laboratories Limited Nalidixic acid 500mg Tablet 50's: 233.50 MRP
NALIDIXIN Suspension Pharmadesh Laboratories Limited Nalidixic acid 300mg/5ml Suspension 50ml: 30.75 MRP
NALIGRAM The Acme Laboratories Ltd. Nalidixic acid 500mg Tablet 100's: 401.00.00 MRP
NALIGRAM Suspension The Acme Laboratories Ltd. Nalidixic acid 300mg/5ml Suspension 50ml, 100ml: 30.46 & 56.86 MRP
NALITRUM Salton Pharmaceuticals Ltd. Nalidixic acid 300mg/5ml Suspension 50ml: 30.00 MRP
NEBACTIL Beximco Pharmaceuticals Ltd Nalidixic Acid BP 300mg/5ml Suspension 50ml: 41.73 MRP